Shares of drug research company Quintiles Transnational Holdings ( id="symbol_Q.N_0"> Q.N ) rose as much as 11 percent in its market debut, valuing the company at as much as $5.73 billion. _0"> The Durham, North Carolina-based clinical trials company's initial public offerings is the largest among the 11 expected to be priced this week. The week could see the highest IPO volume since late 2007, according to market data firm Ipreo. Other offerings that have been priced this week include those of residential mortgage company PennyMac Financial Services Inc ( id="symbol_PFSI.N_1"> PFSI.N ) and biotech company Receptos Inc ( id="symbol_RCPT.O RCPT.O ). _2"> Quintiles raised $947 million in its IPO, more than planned, as it had priced 23.7 million shares at $40 each, compared with its plan to sell 19.7 million shares at $36 to $40 each. Quintiles, founded in 1982, is backed by private equity players Bain Capital LLC and TPG Capital